These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 20217513)
61. A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. George RE; Joseph S Saudi Pharm J; 2014 Nov; 22(5):403-10. PubMed ID: 25473328 [TBL] [Abstract][Full Text] [Related]
62. Gastrointestinal hormones and the regulation of β-cell mass. Lavine JA; Attie AD Ann N Y Acad Sci; 2010 Nov; 1212():41-58. PubMed ID: 21039588 [TBL] [Abstract][Full Text] [Related]
64. Optogenetic therapeutic strategies for diabetes mellitus. Deng X; Peng D; Yao Y; Huang K; Wang J; Ma Z; Fu J; Xu Y J Diabetes; 2024 Jun; 16(6):e13557. PubMed ID: 38751366 [TBL] [Abstract][Full Text] [Related]
65. In vitro proliferation of adult human beta-cells. Rutti S; Sauter NS; Bouzakri K; Prazak R; Halban PA; Donath MY PLoS One; 2012; 7(4):e35801. PubMed ID: 22563404 [TBL] [Abstract][Full Text] [Related]
67. A critical review of mathematical models and data used in diabetology. Boutayeb A; Chetouani A Biomed Eng Online; 2006 Jun; 5():43. PubMed ID: 16808835 [TBL] [Abstract][Full Text] [Related]
68. Gut and adipocyte peptides. Bloomgarden ZT Diabetes Care; 2006 Feb; 29(2):450-6. PubMed ID: 16443906 [No Abstract] [Full Text] [Related]
69. When does diabetes start? Early detection and intervention in type2 diabetes mellitus. Gómez-Peralta F; Abreu C; Cos X; Gómez-Huelgas R Rev Clin Esp (Barc); 2020; 220(5):305-314. PubMed ID: 32107016 [TBL] [Abstract][Full Text] [Related]
70. Cytokine-driven beta-cell production in vivo. Worchel HN; Magnuson MA Nat Biotechnol; 2014 Jan; 32(1):63-4. PubMed ID: 24406931 [No Abstract] [Full Text] [Related]
71. Preservation of beta-cell function in type 2 diabetes. Nyalakonda K; Sharma T; Ismail-Beigi F Endocr Pract; 2010; 16(6):1038-55. PubMed ID: 21030360 [TBL] [Abstract][Full Text] [Related]
72. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651 [TBL] [Abstract][Full Text] [Related]
73. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. van Genugten RE; van Raalte DH; Diamant M Diabetes Obes Metab; 2012 Feb; 14(2):101-11. PubMed ID: 21752172 [TBL] [Abstract][Full Text] [Related]
74. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803 [TBL] [Abstract][Full Text] [Related]
75. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194 [TBL] [Abstract][Full Text] [Related]
76. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698 [TBL] [Abstract][Full Text] [Related]
77. Associations between the levels of circulating inflammatory adipokines and the risk of type 2 diabetes in Chinese male individuals: A case-control study. Sun X; Qiu WW; Wu J; Ding SL; Wu RZ J Clin Lab Anal; 2023 Mar; 37(6):e24875. PubMed ID: 37003602 [TBL] [Abstract][Full Text] [Related]
78. Increased serum cystatin C levels and responses of pancreatic α- and β-cells in type 2 diabetes. Yuan HQ; Miao JX; Xu JP; Zhu SX; Xu F; Wang XH; Wang CH; Yu C; Wang XQ; Su JB; Zhang DM Endocr Connect; 2022 Mar; 11(3):. PubMed ID: 35179515 [TBL] [Abstract][Full Text] [Related]
79. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes. Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969 [TBL] [Abstract][Full Text] [Related]